Who are HyQvia's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cuvitru 20 % Injectable Solution, IgPro20, Immune Globulin (Human), Intravenous immune globulin G, IgM rich Immunoglobin, IV treatment with IGSC, 10%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyqvia.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

HyQvia — Competitive Intelligence Brief

HyQvia (HyQvia) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin. Area: Immunology.

marketed Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement Immunology Biologic Live · refreshed every 30 min

Target snapshot

HyQvia (HyQvia) — Takeda.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HyQvia TARGET	HyQvia	Takeda	marketed	Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin	Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement
Cuvitru 20 % Injectable Solution	Cuvitru 20 % Injectable Solution	University of Edinburgh	marketed	Immunoglobulin replacement therapy	Fc receptors and complement system (via IgG antibodies)
IgPro20	IgPro20	CSL Behring	marketed	Immunoglobulin replacement therapy	Polyclonal IgG (multiple epitopes)
Immune Globulin (Human)	Immune Globulin (Human)	Grifols Therapeutics LLC	marketed	Immunoglobulin replacement therapy	Multiple pathogenic antigens and pathogens (non-specific)
Intravenous immune globulin G	Intravenous immune globulin G	Rutgers, The State University of New Jersey	marketed	Immunoglobulin replacement therapy / Immunomodulator	Multiple (polyclonal IgG antibodies targeting various pathogens and self-antigens)
IgM rich Immunoglobin	IgM rich Immunoglobin	Sir Takhtasinhji General Hospital	marketed	Immunoglobulin replacement therapy	IgM antibodies; complement system (C1q)
IV treatment with IGSC, 10%	IV treatment with IGSC, 10%	Baxalta now part of Shire	phase 3	Immunoglobulin replacement therapy	Fc receptors, complement system, pathogenic antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin class)

Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HyQvia — Competitive Intelligence Brief. https://druglandscape.com/ci/hyqvia. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab